IP Library Patent Application 15355663
Patent Application
App. No. 15/355,663

PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/355,663
Abstract

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

Claims (9)

1 . A mutant chondroitinase AC protein comprising an amino acid sequence of chondroitinase AC (SEQ ID NO: 5) truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.

2 . The mutant chondroitinase AC protein of claim 1 , further comprising a deletion of about 1 to about 275 amino acids from the C-terminus of chondroitinase AC (SEQ ID NO: 5).

3 . The mutant chondroitinae AC protein of claim 2 , wherein the mutant chondroitinase AC protein is selected from SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.

4 . A composition comprising a mutant chondroitinase AC protein comprising an amino acid sequence of chondroitinase AC (SEQ ID NO: 5) truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.

5 . The composition of claim 4 , wherein the mutant chondroitinase AC protein further comprises a deletion of about 1 to about 275 amino acids from the C-terminus of chondroitinase AC (SEQ ID NO: 5).

6 . The composition of claim 5 , wherein the mutant chondroitinase AC protein is selected from SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.

7 . The composition of claim 5 , wherein the composition further comprises molecules that block action of neurite growth inhibitors, molecules that promote neurite growth, neurotrophic factors, neuregulins, neural cell adhesion molecule L1, growth factors, phosphodiesterase inhibitors, diagnostic molecules, therapeutic molecules, or a combination thereof.

8 . The composition of claim 5 , further comprising a pharmaceutically acceptable excipient.

9 . A recombinant nucleic acid comprising a sequence encoding a mutant chondroitinase AC protein, wherein the mutant chondroitinase AC protein comprises an amino acid sequence of SEQ ID NO: 5 truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2018
From: GRUSKIN, ELLIOTT A.; CAGGIANO, ANTHONY O.; ROY, GARGI; D'SOUZA, ROHINI
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 046759/0278 →